Scarica l'app Stockscreener
1.87
8.72%
0.15
Pre-mercato:
1.87
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HRTX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.72
Aprire:
$1.71
Volume 24 ore:
1.89M
Relative Volume:
0.99
Capitalizzazione di mercato:
$285.29M
Reddito:
$137.74M
Utile/perdita netta:
$-27.97M
Rapporto P/E:
-11.69
EPS:
-0.16
Flusso di cassa netto:
$-9.61M
1 W Prestazione:
-13.82%
1M Prestazione:
-2.60%
6M Prestazione:
+57.14%
1 anno Prestazione:
-37.67%
Intervallo 1D:
$1.71
$1.88
Intervallo di 1 settimana:
$1.70
$2.255
Portata 52W:
$1.04
$3.93
Heron Therapeutics Inc Stock (HRTX) Company Profile
Nome
Heron Therapeutics Inc
Settore
Industria
Telefono
(858) 251-4400
Indirizzo
4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO, CA
Confronta HRTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HRTX
Heron Therapeutics Inc
|
1.87 | 331.06M | 137.74M | -27.97M | -9.61M | -0.16 |
|
ONC
Beigene Ltd Adr
|
225.77 | 25.49B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
434.38 | 110.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.32 | 38.69M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
584.99 | 59.13B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
69.53 | 5.64B | 0 | -153.72M | -103.81M | -2.00 |
Heron Therapeutics Inc Stock (HRTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-06-13 | Iniziato | Rodman & Renshaw | Buy |
| 2024-04-23 | Iniziato | CapitalOne | Overweight |
| 2024-03-13 | Reiterato | Needham | Buy |
| 2020-05-27 | Iniziato | Guggenheim | Buy |
| 2020-02-20 | Reiterato | Needham | Buy |
| 2019-01-16 | Reiterato | Needham | Buy |
| 2018-04-05 | Iniziato | Evercore ISI | Outperform |
| 2018-03-19 | Reiterato | Mizuho | Buy |
| 2018-03-01 | Reiterato | Needham | Buy |
| 2018-01-03 | Iniziato | Leerink Partners | Outperform |
| 2017-09-27 | Iniziato | Northland Capital | Outperform |
| 2017-02-27 | Iniziato | Needham | Buy |
| 2016-10-26 | Iniziato | Aegis Capital | Buy |
| 2016-09-06 | Ripresa | Lake Street | Buy |
| 2016-05-03 | Iniziato | Cantor Fitzgerald | Buy |
| 2015-12-10 | Iniziato | Lake Street | Buy |
| 2015-09-23 | Reiterato | Leerink Partners | Outperform |
| 2015-09-02 | Iniziato | BofA/Merrill | Buy |
| 2015-08-03 | Reiterato | Brean Capital | Buy |
| 2015-06-30 | Reiterato | JMP Securities | Mkt Outperform |
| 2015-06-19 | Reiterato | Leerink Partners | Outperform |
| 2014-08-07 | Iniziato | Noble Financial | Buy |
Mostra tutto
Heron Therapeutics Inc Borsa (HRTX) Ultime notizie
J. Goldman & Co LP Acquires Shares of 270,100 Heron Therapeutics, Inc. (NASDAQ:HRTX) - MarketBeat
300,000 Shares in Heron Therapeutics, Inc. (NASDAQ:HRTX) Bought by Bridgeway Capital Management LLC - MarketBeat
What is Northland Capmk's Estimate for HRTX Q2 Earnings? - MarketBeat
Clearline Capital LP Has $2.77 Million Stock Holdings in Heron Therapeutics, Inc. (NASDAQ:HRTX) - MarketBeat
Heron Therapeutics (NASDAQ:HRTX) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat
Heron Therapeutics Sees Unusually Large Options Volume (NASDAQ:HRTX) - MarketBeat
Results: Heron Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates - Yahoo Finance
Heron Therapeutics, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates - simplywall.st
Heron Therapeutics: Q1 Paints A Potentially Rosy Picture For 2025 (NASDAQ:HRTX) - Seeking Alpha
Heron settles patent dispute with Viatris over antiemetic agents - MSN
Heron Therapeutics, Inc. (NASDAQ:HRTX) Q1 2025 Earnings Call Transcript - Insider Monkey
Heron Therapeutics First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Heron Therapeutics Reports Strong Q1 2025 Results - TipRanks
Heron Therapeutics Q1 2025 Earnings: Strong Growth Amid Challenges - TipRanks
Heron Therapeutics Q1 2025 Earnings Call Transcript - MarketBeat
Heron Therapeutics (HRTX) Resolves Patent Dispute with Viatris - GuruFocus
Heron Settles Patent Litigation With Mylan Over Cinvanti, Aponvie; Shares Rise - marketscreener.com
Heron stock up as Viatris patent dispute ends (HRTX:NASDAQ) - Seeking Alpha
Compared to Estimates, Heron Therapeutics (HRTX) Q1 Earnings: A Look at Key Metrics - Yahoo Finance
Earnings call transcript: Heron Therapeutics beats Q1 2025 expectations, stock surges - Investing.com Canada
Heron Therapeutics (HRTX) Q1 Earnings and Revenues Top Estimates - Yahoo Finance
HRTX Achieves Record Q1 Revenue, Surpassing Expectations | HRTX Stock News - GuruFocus
Heron Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Corporate Updates - The Malaysian Reserve
Heron Therapeutics (HRTX) Settles Patent Disputes with Mylan Pharmaceuticals | HRTX Stock News - GuruFocus
Heron Therapeutics Q1 2025 Financial Results - TradingView
Heron Therapeutics: Q1 Earnings Snapshot - marketscreener.com
Heron Therapeutics settles patent litigation with Mylan By Investing.com - Investing.com India
Heron Therapeutics Announces Settlement With Mylan Related To Cinvanti® And Aponvie® Patent Litigations - marketscreener.com
Heron Therapeutics Announces Settlement with Mylan Related to CINVANTI® and APONVIE® Patent Litigations - PR Newswire
Invesco Ltd. Grows Stock Holdings in Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World
Heron Therapeutics (HRTX) Awaits Q1 Earnings Report - GuruFocus
Marshall Wace LLP Cuts Position in Heron Therapeutics, Inc. (NASDAQ:HRTX) - MarketBeat
Heron Therapeutics (HRTX) Projected to Post Earnings on Tuesday - MarketBeat
Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Purchased by JPMorgan Chase & Co. - MarketBeat
Adage Capital Partners GP L.L.C. Decreases Stake in Heron Therapeutics, Inc. (NASDAQ:HRTX) - MarketBeat
Renaissance Technologies LLC Has $1.82 Million Stake in Heron Therapeutics, Inc. (NASDAQ:HRTX) - MarketBeat
Heron Therapeutics Inc expected to post a loss of 1 cent a shareEarnings Preview - TradingView
Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Sold by LPL Financial LLC - Defense World
Healthy Upside Potential: Heron Therapeutics Inc (HRTX) - Sete News
American Society of Anesthesiologists Announces Heron Therapeutics as Industry Supporter for Seventh Year | Newswise - Newswise
HRTX stock rated a Buy by Rodman & Renshaw - knoxdaily.com
It would be worthwhile to take a closer look at Heron Therapeutics Inc (HRTX) - uspostnews.com
Heron Therapeutics (HRTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release - Yahoo Finance
Heron Therapeutics Appoints Mark Hensley as COO - TipRanks
Heron Therapeutics Names Mark Hensley as COO - marketscreener.com
Heron Therapeutics Inc Azioni (HRTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.17%
0.76%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):